June 21 (Reuters) - Cara Therapeutics Inc:
* Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment
* Cara Therapeutics - based on guidance of idmc, trial will continue to test 2 doses of cr845 versus placebo in up to 450 patients undergoing abdominal surgery
* Cara Therapeutics Inc - trial will continue to test two doses of cr845 and aims to enroll up to 450 patients
* Cara Therapeutics Inc - both doses of cr845 well tolerated
* Cara Therapeutics Inc - trial completion expected in q4 of 2017 for cr845 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.